| pubmed-article:20166953 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20166953 | lifeskim:mentions | umls-concept:C0006784 | lld:lifeskim |
| pubmed-article:20166953 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:20166953 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:20166953 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:20166953 | lifeskim:mentions | umls-concept:C2346874 | lld:lifeskim |
| pubmed-article:20166953 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:20166953 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20166953 | pubmed:dateCreated | 2010-4-8 | lld:pubmed |
| pubmed-article:20166953 | pubmed:abstractText | The physiological roles of calpains are discussed, as are the associated pathological disorders that result from their over-activation. We also present practical information for establishing functional inhibition assays and an overview of X-ray crystal structures of calpain-inhibitor complexes to aid inhibitor design. These structures reveal the expected extended beta-strand conformation for the inhibitor backbone, a geometry that has been engineered into inhibitors with the introduction of either an N-terminal heterocycle or a macrocycle that links the P(1) and P(3) residues. The structure and function of all the main classes of inhibitors are reviewed, with most examples being classified according to the nature of the C-terminal reactive warhead group that reacts with the active site cysteine of calpains. These inhibitor classes include epoxysuccinate derivatives, aldehydes, aldehyde prodrugs (hemiacetals) and alpha-keto carbonyl compounds. Inhibitors derived from the endogenous inhibitor calpastatin and examples lacking a warhead, are now known and these are also discussed. | lld:pubmed |
| pubmed-article:20166953 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20166953 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20166953 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20166953 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20166953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20166953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20166953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20166953 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20166953 | pubmed:issn | 1873-4294 | lld:pubmed |
| pubmed-article:20166953 | pubmed:author | pubmed-author:PietschMarkus... | lld:pubmed |
| pubmed-article:20166953 | pubmed:author | pubmed-author:AbellAndrew... | lld:pubmed |
| pubmed-article:20166953 | pubmed:author | pubmed-author:ChuaKrystle... | lld:pubmed |
| pubmed-article:20166953 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20166953 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:20166953 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20166953 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20166953 | pubmed:pagination | 270-93 | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:meshHeading | pubmed-meshheading:20166953... | lld:pubmed |
| pubmed-article:20166953 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20166953 | pubmed:articleTitle | Calpains: attractive targets for the development of synthetic inhibitors. | lld:pubmed |
| pubmed-article:20166953 | pubmed:affiliation | School of Chemistry & Physics, The University of Adelaide, Adelaide, South Australia 5005, Australia. markus.pietsch@adelaide.edu.au | lld:pubmed |
| pubmed-article:20166953 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20166953 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:20166953 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20166953 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
